Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : July 31, 2017

Capitalcube gives Aurinia Pharmaceuticals, Inc. a score of 32.

Our analysis is based on comparing Aurinia Pharmaceuticals, Inc. with the following peers – Cadus Corporation, Regeneron Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc. and Aeterna Zentaris Inc. (KDUS-US, REGN-US, KERX-US and AEZS-US).

Investment Outlook

Aurinia Pharmaceuticals, Inc. has a fundamental score of 32 and has a relative valuation of NEUTRAL.

Fundamental Score

Access our research and ratings on Aurinia Pharmaceuticals, Inc.

Company Overview

  • With respect to peers, relative outperformance over the last year is in contrast to the more recent underperformance.
  • It trades at a lower Price/Book multiple (2.87) than its peer median (4.05).
  • AUPH-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • AUPH-US‘s relatively low net margins and poor asset turns suggest a problematic operating strategy.
  • Compared with its chosen peers, the company’s annual revenues and earnings change at a slower rate, implying a lack of strategic focus and/or lack of execution success.
  • AUPH-US‘s return on assets currently and over the past five years is around the peer median and suggest that it does not have any particular operational advantages versus peers.
  • AUPH-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful for an analysis between historical growth (using annualized three-year revenue growth) and investor growth expectations (as suggested by P/E or Price/EBITDA) .
  • The company is likely overinvesting in a business with only median returns.
  • AUPH-US currently does not have any debt.

Access our research and ratings on Aurinia Pharmaceuticals, Inc.

Leverage & Liquidity

AUPH-US currently does not have any debt.

  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 0%.
  • Of the 4 chosen peers for the company, only 2 of the stocks have an outstanding debt balance. Companies with no debt include KDUS-US and AEZS-US.

Access the detailed analysis for Aurinia Pharmaceuticals, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
Cadus Corporation 0 118.58 No interest exp 999
Regeneron Pharmaceuticals, Inc. 1.74 2.8 184.95 231.59
Keryx Biopharmaceuticals, Inc. 14.86 5.76 -3.59 -65.1
Aeterna Zentaris Inc. 0 5.6 No interest exp 999
Aurinia Pharmaceuticals Inc. 0 24.59 No interest exp 999
Peer Median 0 5.76 No interest exp 999
Best In Class 1.74 118.58 No interest exp 999

Looking for more metrics and analysis for Aurinia Pharmaceuticals, Inc.?

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company’s pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website